Share on StockTwits

ResMed (NYSE:RMD) Director Peter C. Farrell unloaded 25,000 shares of ResMed stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $50.09, for a total value of $1,252,250.00. Following the transaction, the director now directly owns 304,990 shares of the company’s stock, valued at approximately $15,276,949. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

ResMed (NYSE:RMD) traded down 0.83% during mid-day trading on Thursday, hitting $50.08. 1,237,478 shares of the company’s stock traded hands. ResMed has a 1-year low of $41.52 and a 1-year high of $57.34. The stock’s 50-day moving average is $51.21 and its 200-day moving average is $47.25. The company has a market cap of $7.028 billion and a price-to-earnings ratio of 22.16.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Wednesday, April 23rd. The company reported $0.63 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.64 by $0.01. The company had revenue of $397.80 million for the quarter, compared to the consensus estimate of $401.00 million. During the same quarter last year, the company posted $0.58 earnings per share. ResMed’s revenue was up 3.7% compared to the same quarter last year. On average, analysts predict that ResMed will post $2.49 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on RMD shares. Analysts at Deutsche Bank downgraded shares of ResMed from a “buy” rating to a “hold” rating in a research note on Thursday. They now have a $52.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of ResMed in a research note on Wednesday, June 11th. They now have a $55.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. upgraded shares of ResMed from a “neutral” rating to an “overweight” rating in a research note on Tuesday, June 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the stock. ResMed presently has an average rating of “Hold” and a consensus price target of $46.90.

ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.